Related Experiment Video
Updated: Sep 12, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation
Matthew Wortham1,2, Bastian Ramms1, Chun Zeng1
1Departments of Pediatrics and Cellular and Molecular Medicine, Pediatric Diabetes Research Center, UCSD, La Jolla, California, USA.
Abstract:
Selective and controlled expansion of endogenous β cells has been pursued as a potential therapy for diabetes. Ideally, such therapies would preserve feedback control of β cell proliferation to avoid excessive β cell expansion. Here, we identified a regulator of β cell proliferation whose inactivation resulted in controlled β cell expansion: the protein deacetylase sirtuin 2 (SIRT2). Sirt2 deletion in β cells of mice increased β cell proliferation during hyperglycemia with little effect under homeostatic conditions, indicating preservation of feedback control of β cell mass. SIRT2 restrains proliferation of human islet β cells, demonstrating conserved SIRT2 function. Analysis of acetylated proteins in islets treated with a SIRT2 inhibitor revealed that SIRT2 deacetylates enzymes involved in oxidative phosphorylation, dampening the adaptive increase in oxygen consumption during hyperglycemia. At the transcriptomic level, Sirt2 inactivation has context-dependent effects on β cells, with Sirt2 controlling how β cells interpret hyperglycemia as a stress. Finally, we provide proof of principle that systemic administration of a glucagon-like peptide 1-coupled (GLP1-coupled), Sirt2-targeting antisense oligonucleotide achieves β cell Sirt2 inactivation and stimulates β cell proliferation during hyperglycemia. Overall, these studies identify a therapeutic strategy for increasing β cell mass in diabetes without circumventing feedback control of β cell proliferation. Future work should test the extent to which these findings translate to human β cells from individuals with or without diabetes.
Insights
Scientists discovered that inhibiting Sirtuin 2 (SIRT2) in pancreatic beta cells promotes controlled beta cell proliferation during hyperglycemia, offering a potential diabetes therapy. This approach preserves feedback control, preventing excessive cell growth.
Area of Science:
- Endocrinology and Metabolism
- Cell Biology
- Molecular Medicine
Background:
- Therapies for diabetes aim to expand endogenous pancreatic beta cells while maintaining feedback control.
- Excessive beta cell proliferation must be avoided to prevent complications.
- Identifying regulators of beta cell proliferation is crucial for developing safe and effective treatments.
Purpose of the Study:
- To identify regulators of beta cell proliferation that allow for controlled expansion.
- To investigate the role of Sirtuin 2 (SIRT2) in regulating beta cell mass.
- To explore a novel therapeutic strategy for increasing beta cell mass in diabetes.
Main Methods:
- Genetic deletion of Sirt2 in mouse beta cells.
- Analysis of beta cell proliferation under homeostatic and hyperglycemic conditions.
- Inhibition of SIRT2 in human islets and analysis of acetylated proteins.
- Transcriptomic analysis of Sirt2-inactivated beta cells.
- Systemic administration of GLP1-coupled Sirt2-targeting antisense oligonucleotide in mice.
Main Results:
- Sirt2 deletion in mouse beta cells increased proliferation during hyperglycemia but not under homeostatic conditions, preserving feedback control.
- SIRT2 was found to restrain proliferation in human islet beta cells, indicating conserved function.
- SIRT2 inhibition affected enzymes involved in oxidative phosphorylation and altered the interpretation of hyperglycemia as a stress.
- Systemic administration of an antisense oligonucleotide successfully inactivated SIRT2 in beta cells, stimulating proliferation during hyperglycemia.
Conclusions:
- Sirtuin 2 (SIRT2) acts as a key regulator that restrains beta cell proliferation.
- Inactivating SIRT2 offers a therapeutic strategy to increase beta cell mass in diabetes without disrupting feedback control mechanisms.
- Further research is needed to validate these findings in human beta cells from diabetic and non-diabetic individuals.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Cell Specific Gene Expression
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Metabolism
TGF - β Signaling Pathway
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

